Compare PGZ & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGZ | DRIO |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | 165 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.9M | 60.6M |
| IPO Year | N/A | 2013 |
| Metric | PGZ | DRIO |
|---|---|---|
| Price | $9.76 | $8.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 18.5K | 6.2K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | ★ 1559.02 |
| EPS | N/A | ★ 1.25 |
| Revenue | N/A | ★ $7,394,000.00 |
| Revenue This Year | N/A | $20.27 |
| Revenue Next Year | N/A | $47.58 |
| P/E Ratio | ★ N/A | $6.40 |
| Revenue Growth | N/A | ★ 43.02 |
| 52 Week Low | $9.32 | $0.38 |
| 52 Week High | $10.64 | $17.74 |
| Indicator | PGZ | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 52.26 |
| Support Level | $9.32 | $7.29 |
| Resistance Level | $10.58 | $9.46 |
| Average True Range (ATR) | 0.13 | 0.44 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 23.59 | 56.52 |
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.